Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease

Free Radical Biology and Medicine

Volumn 41, Issue 11, 2006, Pages 1678-1683

  Shishehbor, Mehdi H ^a   Zhang, Renliang ^a   Medina, Hector ^a   Brennan, Marie Luise ^a   Brennan, Danielle M ^a   Ellis, Stephen G ^a   Topol, Eric J ^a   Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Coronary artery disease; F2 isoprostanes; Oxidation; Oxidation products

Indexed keywords

11 HYDROXYICOSATETRAENOIC ACID; 12 HYDROXYICOSATETRAENOIC ACID; 13 HYDROXYOCTADECADIENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; 8 HYDROXYARACHIDONIC ACID; 9 HYDROXYICOSATETRAENOIC ACID; 9 HYDROXYOCTADECADIENOIC ACID; ARACHIDONIC ACID; C REACTIVE PROTEIN; DECANOIC ACID DERIVATIVE; FREE RADICAL; HYDROXYICOSATETRAENOIC ACID; ISOPROSTANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FATTY ACID OXIDATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID PEROXIDATION; MALE; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; TANDEM MASS SPECTROMETRY;

ARACHIDONIC ACID; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; F2-ISOPROSTANES; FATTY ACIDS; FEMALE; FREE RADICALS; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PROGNOSIS;

EID: 33750336749     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.09.001     Document Type: Article

References (37)

1. Berliner J.A., Navab M., Fogelman A.M., et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91 9 (1995) 2488-2496
2. Berliner J., Leitinger N., Watson A., Huber J., Fogelman A., and Navab M. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb. Haemost. 78 1 (1997) 195-199
3. Navab M., Berliner J.A., Watson A.D., et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16 7 (1996) 831-842
4. Hazen S.L. Oxidation and atherosclerosis. Free Radic. Biol. Med. 28 12 (2000) 1683-1684
5. Loscalzo J. Oxidative stress in endothelial cell dysfunction and thrombosis. Pathophysiol. Haemost. Thromb. 32 5--6 (2002) 359-360
6. Harrison D. Oxidative stress and coronary artery disease. Can. J. Cardiol. 14 (1998) 30D-32D (Suppl. D)
7. Diaz M.N., Frei B., Vita J.A., and Keaney Jr. J.F. Antioxidants and atherosclerotic heart disease. N. Engl. J. Med. 337 6 (1997) 408-416
8. Steinberg D., and Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?. Circulation 105 17 (2002) 2107-2111
9. Chisolm G.M., and Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic. Biol. Med. 28 12 (2000) 1815-1826
10. Vivekananthan D.P., Penn M.S., Sapp S.K., Hsu A., and Topol E.J. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361 9374 (2003) 2017-2023
11. Shishehbor M.H., and Hazen S.L. Antioxidant studies need a change of direction. Cleve. Clin. J. Med. 71 4 (2004) 285-288
12. Shishehbor M.H., and Hazen S.L. Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr. Atheroscler. Rep. 6 3 (2004) 243-250
13. Brennan M.L., and Hazen S.L. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr. Opin. Lipidol. 14 4 (2003) 353-359
14. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25 2 (2005) 279-286
15. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 4 (2003) 426-431
16. Shishehbor M.H., Aviles R.J., Brennan M.L., et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289 13 (2003) 1675-1680
17. Agah R., Ellis S., Chase S., et al. Creation of a large-scale genetic data bank for cardiovascular association studies. Am. Heart J. 150 3 (2005) 500-506
18. Zhang R., Brennan M.L., Shen Z., et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J. Biol. Chem. 277 48 (2002) 46116-46122
19. Schultz D., and Harrison D.G. Quest for fire: seeking the source of pathogenic oxygen radicals in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20 6 (2000) 1412-1413
20. Nicholls S.J., and Hazen S.L. Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 25 6 (2005) 1102-1111
21. Meagher E.A., Barry O.P., Lawson J.A., Rokach J., and FitzGerald G.A. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 285 9 (2001) 1178-1182
22. Leeuwenburgh C., Hardy M.M., Hazen S.L., et al. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J. Biol. Chem. 272 3 (1997) 1433-1436
23. Podmore I.D., Griffiths H.R., Herbert K.E., Mistry N., Mistry P., and Lunec J. Vitamin C exhibits pro-oxidant properties. Nature 392 6676 (1998) 559
24. Leeuwenburgh C., Rasmussen J.E., Hsu F.F., Mueller D.M., Pennathur S., and Heinecke J.W. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J. Biol. Chem. 272 6 (1997) 3520-3526
25. Hazen S.L., and Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99 9 (1997) 2075-2081
26. Savenkova M.L., Mueller D.M., and Heinecke J.W. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J. Biol. Chem. 269 32 (1994) 20394-20400
27. Hazell L.J., and Stocker R. Alpha-tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS Lett. 414 3 (1997) 541-544
28. Brennan M.L., and Hazen S.L. Amino acid and protein oxidation in cardiovascular disease. Amino Acids 25 3--4 (2003) 365-374
29. Heinecke J.W. Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. Arterioscler. Thromb. Vasc. Biol. 21 8 (2001) 1261-1264
30. Heinecke J.W. Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. Free Radic. Biol. Med. 32 11 (2002) 1090-1101
31. Lawson J.A., Rokach J., and FitzGerald G.A. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem 274 35 (1999) 24441-24444
32. Pratico D., Iuliano L., Mauriello A., et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100 8 (1997) 2028-2034
33. Reilly M.P., Pratico D., Delanty N., et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98 25 (1998) 2822-2828
34. Mallat Z., Nakamura T., Ohan J., et al. The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J. Clin. Invest. 103 3 (1999) 421-427
35. Spittle M.A., Hoenich N.A., Handelman G.J., Adhikarla R., Homel P., and Levin N.W. Oxidative stress and inflammation in hemodialysis patients. Am. J. Kidney Dis. 38 6 (2001) 1408-1413
36. Morrow J.D., Frei B., Longmire A.W., et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 332 18 (1995) 1198-1203
37. Montine T.J., Markesbery W.R., Morrow J.D., and Roberts II L.J. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 44 3 (1998) 410-413